A PHASE 2 TRIAL OF LENVATINIB (E7080) IN SUBJECTS WITH IODINE-131 REFRACTORY DIFFERENTIATED THYROID CANCER TO EVALUATE WHETHER AN ORAL STARTING DOSE OF 18 MG DAILY WILL PROVIDE COMPARABLE EFFICACY TO A 24 MG STARTING DOSE, BUT HAVE A BETTER SAFETY PROFILE: